Aktuellt
SENASTE
Expanding clinical evidence and market opportunities is the key to Biovica’s future opportunities once approved. This year’s US SABCS conference (7-10 December) will feature three studies where Biovica’s DiviTum is featured monitoring treatment in women with metastatic breast cancer (mBC).
LÄS MER
